主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
作者:聂晓欢1 张跃华2 高亭午3 张易欣1 周玮月1 李美艳1 姜黎黎1 王菊荣1
英文作者:Nie Xiaohuan1 Zhang Yuehua2 Gao Tingwu3 Zhang Yixin1 Zhou Weiyue1 Li Meiyan1 Jiang Lili1 Wang Jurong1
单位:1河北省邯郸市中心医院妇科,邯郸056000;2河北省邯郸市第一医院妇科,邯郸056000;3保时捷管理咨询有限公司咨询部门,北京100020
英文单位:1Department of Gynecology Handan Central Hospital Hebei Province Handan 056000 China; 2Department of Gynecology Handan First Hospital Hebei Province Handan 056000 China; 3Consulting Team, Porsche Management Consulting Ltd. Beijing 100020 China
英文关键词:Cervicalcancer;MicroRNA;Cervicalhigh-gradesquamousintraepitheliallesion
目的 探讨微小RNA(miR)-126-3p、miR-199a-3p、miR-150-5p、miR-221-3p在宫颈癌患者血清中的表达及早期筛查的意义。方法 选取2020年12月至2022年12月河北省邯郸市中心医院住院治疗患者及同期于该院行体检的、宫颈癌前筛查未见明显异常的健康女性作为研究对象。根据健康状况不同分为宫颈癌组(61例)、宫颈高级别鳞状上皮内病变(HSIL)组(40例)和对照组(健康女性,40例)。比较组间以上4种miR的相对表达情况差异,分析miR相对表达水平与宫颈癌患者临床及病理指标的相关性及对宫颈癌的预测价值。结果 宫颈癌组患者血清中miR-126-3p、miR-199a-3p的相对表达水平低于对照组和HSIL组,miR-150-5p、miR-221-3p 的相对表达水平高于对照组和HSIL组,差异均有统计学意义[(0.31±0.06)比(0.50±0.08)、(0.38±0.08),(2.56±0.36)比(3.38±0.51)、(3.25±0.60),(2.91±0.49)比(1.42±0.49)、(2.20±0.53),(3.24±0.96)比(1.83±0.63)、(2.02±0.62)](均P<0.05)。宫颈癌组患者国际妇产科联盟分期Ⅰ期+Ⅱ期和Ⅲ期者血清miR-126-3p、miR-221-3p相对表达水平差异有统计学意义(P<0.05)。miR-126-3p联合miR-199a-3p检测预测宫颈癌的敏感度为95.0%、特异度为76.3%,miR-150-5p联合miR-221-3p检测的敏感度为91.7%、特异度为85.0%。结论 miR-126-3p、miR-199a-3p、miR-150-5p、miR-221-3p 在宫颈癌和癌前病变患者血清中异常表达,与宫颈癌的发生发展密切相关,对于宫颈癌诊治可能提供新的靶点。miR-150-5p联合miR-221-3p检测预测宫颈癌的敏感度及特异度均较高,可以考虑作为宫颈癌早期筛查的标志物。
Objective To investigate the expression of microRNA(miR)-126-3p, miR-199a-3p, miR-150-5p, and miR-221-3p in the serum of cervical cancer patients and their significance for early screening. Methods Patients who were hospitalized at Handan Central Hospital, Hebei Province from December 2020 to December 2022 and healthy women who underwent physical examinations in the hospital during the same period and had no obvious abnormalities in cervical cancer pre screening were selected as the research subjects. According to different health conditions, they were divided into cervical cancer group(61 cases), cervical high-grade squamous intraepithelial lesion(HSIL) group(40 cases), and control group(40 healthy women). The relative expression differences of the above four miRs among the groups were compared, and the correlation between the expression level of miR and the clinical and pathological parameters of cervical cancer patients and the predictive value of miR in cervical cancer were analyzed. Results The relative expression levels of miR-126-3p and miR-199a-3p in the cervical cancer group were lower than those in the control group and HSIL group, while the relative expression levels of miR-150-5p and miR-221-3p were higher than those in the control group and HSIL group [(0.31±0.06) vs (0.50±0.08), (0.38±0.08); (2.56±0.36) vs (3.38±0.51), (3.25±0.60); (2.91±0.49) vs (1.42±0.49), (2.20±0.53); (3.24±0.96) vs (1.83±0.63), (2.02±0.62)](all P<0.05). There were significant differences in the relative expression levels of miR-126-3p and miR-221-3p in stages Ⅰ+Ⅱ stage and Ⅲ of the International Federation of Gynecology and Obstetrics in the cervical cancer group (P<0.05). The sensitivity and specificity of miR-126-3p combined with miR-199a-3p detection for predicting cervical cancer were 95.0% and 76.3%, while the sensitivity and specificity of miR-150-5p combined with miR-221-3p detection were 91.7% and 85.0%, respectively. Conclusions The abnormal expressions of miR-126-3p, miR-199a-3p, miR-150-5p, and miR-221-3p in the serum of patients with cervical cancer and precancerous lesions are closely related to the occurrence and development of cervical cancer, which may provide new targets for the diagnosis and treatment of cervical cancer. The combined detection of miR-150-5p and miR-221-3p has high sensitivity and specificity in predicting cervical cancer, and can be considered as a biomarker for early screening of cervical cancer.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。